N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=333 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.71; -0.40 Units on a scale — p=<0.001
Phase 3 N=351 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.64; -0.49 Units on a scale — p=0.006
Phase 3 N=324 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days. — -0.68; -0.57 Units on a scale — p=0.102
N/A N=93 Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
Allergic Rhinitis · Asthma · Latent Tuberculosis
Primary: IFN-y Protein Response in Mucosal Lining Fluid — NA; 3.29; 9.42; 8.20 pg/hr/ml
Phase 4 N=64 Intranasal Steroids and Oxymetazoline in Allergic Rhinitis
Allergic Rhinitis
Primary: Total Nasal Congestion Symptom Score — 94; 70; 75; 68 units on a scale
N/A N=52 Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion
Nasal Congestion and Inflammations
Primary: Primary Effectiveness — -0.87; -0.44 score on a scale
Phase 2 N=21 A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Allergic Rhinitis
Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302
N/A N=33 InFlux System for Nasal Breathing Improvement
Nasal Airway Obstruction
Primary: Incidence of Unanticipated Serious Adverse Device Effects — 0 events
Phase 4 N=39 Allergic Rhinitis Changes the Sinus Microbiome
Seasonal Allergic Rhinitis
Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391
N/A N=40 Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
Seasonal Allergic Rhinitis
Primary: Global Assessment — 1.7; 1.4 units on a scale — p=0.372
Phase 3 N=575 Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)
Seasonal Allergic Rhinitis
Primary: Mean Change From Baseline in Daily Reflective Nasal Congestion Score — 2.357; 2.271; -0.394; -0.412 Scores on a scale
Phase 4 N=41 NasoNeb Delivery of an Intranasal Steroid
Perennial Allergic Rhinitis
Primary: Change in Nasal Peak Inspiratory Flow (NPIF) — 36.41; 18.71 liters/min
Phase 4 N=34 Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)
Adenoids
Primary: Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score — 3.89; 1.26 Score on a scale
Phase 4 N=53 Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis) · Allergic Rhinosinusitis · Chronic Eosinophilic Rhinosinusitis
Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale
Phase 3 N=323 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Bilateral Nasal Polyposis
Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.26; -0.53; -0.56; -0.67 units on a scale
Phase 1 N=16 Potential for Cortisol Suppression With the Use of High Volume Nasal Mometasone Irrigations in Varying Dosages.
Chronic Rhinosinusitis (Diagnosis)
Primary: Morning "AM" Serum Cortisol Level — 17.35; 14.48 mcg/dL
Phase 4 N=42 The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation
Nasal Obstruction
Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…
N/A N=12 Impact of Symbiofilm On Nasal Microbiota
Rhinosinusitis Chronic · Microbiome
Primary: Comparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2) — 2.041; 2.114 Shannon Index — p=0.908
Phase 4 N=80 Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis
Non-allergic Rhinitis
Primary: Change in Visual Analogue Scale for Major Nasal Symptoms — 3.66; 4.29; 4.49; 5.6 score on a scale
Phase 4 N=50 Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction
Nasal Obstruction Present Finding
Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale
Phase 2 N=539 Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)
Rhinitis · Seasonal Rhinitis
Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Nasal Congestion Score — -0.460; -0.499; -0.508; -0.461 Units on a Scale — p=0.4912
Phase 3 N=748 A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
Nasal Polyps
Primary: Change From Baseline in Congestion/Obstruction Score — -0.56; -0.42 score on a scale — p=0.0007
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 3 N=323 Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
Bilateral Nasal Polyposis
Primary: Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms — -0.24; -0.59; -0.68; -0.62 units on a scale
Phase 3 N=407 Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal Polyps
Primary: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52 — 0.0; -1.0 Scores on a scale — p=<0.001
N/A N=32 Comparison of Nasal Steroids After FESS in CRSwNP
Sinusitis · Nasal Polyps
Primary: SNOT-22 Scores — 31.5; 10.29; 15.88 units on a scale
N/A N=17 Effects of Radiofrequency Ablation of Posterior Nasal Nerves on Inflammatory Cytokines, Peak Nasal Inspiratory Flow, and Nasal Blood Flow in Patients With Chronic Rhinitis
Chronic Rhinitis
Primary: Nasal Congestion as Assessed by the Peak Nasal Inspiratory Flow (PNIF) — 90 Liters Per Minute
N/A N=50 A User Study of the Soniflow System for Nasal Congestion Relief
Nasal Congestion
Primary: Total Nasal Symptom Score — 2.0 score on a scale
Phase 3 N=91 Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays
Otitis Media, Serous · Negative Middle Ear Pressure · Rhinitis
Primary: Number of Subjects With Complete Normalization of Abnormal Tympanometry, Regardless of Additional Treatment — 7; 12 participants — p=0.18